These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32998843)

  • 1. [Ototoxicity in cancer survivors: experience and proposal of a surveillance protocol].
    Sánchez-Canteli M; Núñez-Batalla F; Martínez-González P; de Lucio-Delgado A; Villegas-Rubio JA; Gómez-Martínez JR; Llorente-Pendás JL
    An Pediatr (Engl Ed); 2020 Sep; ():. PubMed ID: 32998843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ototoxicity in cancer survivors: Experience and proposal of a surveillance protocol.
    Sánchez-Canteli M; Núñez-Batalla F; Martínez-González P; de Lucio-Delgado A; Antonio Villegas-Rubio J; Gómez-Martínez JR; Luis Llorente-Pendás J
    An Pediatr (Engl Ed); 2021 Nov; 95(5):290-297. PubMed ID: 34702687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
    van As JW; van den Berg H; van Dalen EC
    Cochrane Database Syst Rev; 2019 May; 5(5):CD009219. PubMed ID: 31063591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platinum-induced hearing loss after treatment for childhood cancer.
    van As JW; van den Berg H; van Dalen EC
    Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD010181. PubMed ID: 27486906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term auditory follow-up in the management of pediatric platinum-induced ototoxicity.
    Fetoni AR; Brigato F; De Corso E; Lucidi D; Sergi B; Scarano E; Galli J; Ruggiero A
    Eur Arch Otorhinolaryngol; 2022 Oct; 279(10):4677-4686. PubMed ID: 35024956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
    van As JW; van den Berg H; van Dalen EC
    Cochrane Database Syst Rev; 2014 Jul; (7):CD009219. PubMed ID: 24984156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ototoxicity in childhood: Recommendations of the CODEPEH (Commission for the Early Detection of Childhood Hearing Loss) for prevention and early diagnosis.
    Núñez-Batalla F; Jáudenes-Casaubón C; Sequí-Canet JM; Vivanco-Allende A; Zubicaray-Ugarteche J
    Acta Otorrinolaringol Esp (Engl Ed); 2022; 73(4):255-265. PubMed ID: 35872300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
    van As JW; van den Berg H; van Dalen EC
    Cochrane Database Syst Rev; 2012 May; (5):CD009219. PubMed ID: 22592737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study.
    Langer T; Clemens E; Broer L; Maier L; Uitterlinden AG; de Vries ACH; van Grotel M; Pluijm SFM; Binder H; Mayer B; von dem Knesebeck A; Byrne J; van Dulmen-den Broeder E; Crocco M; Grabow D; Kaatsch P; Kaiser M; Spix C; Kenborg L; Winther JF; Rechnitzer C; Hasle H; Kepak T; van der Kooi AF; Kremer LC; Kruseova J; Bielack S; Sorg B; Hecker-Nolting S; Kuehni CE; Ansari M; Kompis M; van der Pal H; Parfitt R; Deuster D; Matulat P; Tillmanns A; Tissing WJE; Beck JD; Elsner S; Am Zehnhoff-Dinnesen A; van den Heuvel-Eibrink MM; Zolk O;
    Eur J Cancer; 2020 Oct; 138():212-224. PubMed ID: 32905960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and associated risk factors for platinum-induced ototoxicity in pediatric patients.
    Waissbluth S; Del Valle Á; Chuang A; Becker A
    Int J Pediatr Otorhinolaryngol; 2018 Aug; 111():174-179. PubMed ID: 29958605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic Determinants of Ototoxicity During and After Childhood Cancer Treatment: Protocol for the PanCareLIFE Study.
    Clemens E; Meijer AJ; Broer L; Langer T; van der Kooi AL; Uitterlinden AG; de Vries A; Kuehni CE; Garrè ML; Kepak T; Kruseova J; Winther JF; Kremer LC; van Dulmen-den Broeder E; Tissing WJ; Rechnitzer C; Kenborg L; Hasle H; Grabow D; Parfitt R; Binder H; Carleton BC; Byrne J; Kaatsch P; Am Zehnhoff-Dinnesen A; Zolk O; van den Heuvel-Eibrink MM
    JMIR Res Protoc; 2019 Mar; 8(3):e11868. PubMed ID: 30888333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-effects study.
    Clemens E; de Vries AC; Pluijm SF; Am Zehnhoff-Dinnesen A; Tissing WJ; Loonen JJ; van Dulmen-den Broeder E; Bresters D; Versluys B; Kremer LC; van der Pal HJ; van Grotel M; van den Heuvel-Eibrink MM;
    Eur J Cancer; 2016 Dec; 69():77-85. PubMed ID: 27821322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of platinum-induced ototoxicity in pediatric patients in Quebec.
    Peleva E; Emami N; Alzahrani M; Bezdjian A; Gurberg J; Carret AS; Daniel SJ
    Pediatr Blood Cancer; 2014 Nov; 61(11):2012-7. PubMed ID: 24976616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platinum-induced ototoxicity in pediatric cancer survivors: GSTP1 c.313A>G variant association.
    Sherief LM; Rifky E; Attia M; Ahmed R; Kamal NM; Oshi MAM; Hanna D
    Medicine (Baltimore); 2022 Nov; 101(45):e31627. PubMed ID: 36397425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility and first results of a prospective cohort study to investigate cisplatin-associated ototoxicity amongst cancer patients in South Africa.
    Paken J; Govender CD; Pillay M; Ayele BT; Sewram V
    BMC Cancer; 2021 Jul; 21(1):822. PubMed ID: 34271863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
    van As JW; van den Berg H; van Dalen EC
    Cochrane Database Syst Rev; 2016 Sep; 9(9):CD009219. PubMed ID: 27669661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss.
    Bertolini P; Lassalle M; Mercier G; Raquin MA; Izzi G; Corradini N; Hartmann O
    J Pediatr Hematol Oncol; 2004 Oct; 26(10):649-55. PubMed ID: 15454836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma.
    Bass JK; Huang J; Onar-Thomas A; Chang KW; Bhagat SP; Chintagumpala M; Bartels U; Gururangan S; Hassall T; Heath JA; McCowage G; Cohn RJ; Fisher MJ; Robinson G; Broniscer A; Gajjar A; Gurney JG
    Pediatr Blood Cancer; 2014 Apr; 61(4):601-5. PubMed ID: 24504791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hearing loss after platinum treatment is irreversible in noncranial irradiated childhood cancer survivors.
    Clemens E; de Vries AC; Am Zehnhoff-Dinnesen A; Tissing WJ; Loonen JJ; Pluijm SF; van Dulmen-den Broeder E; Bresters D; Versluys B; Kremer LC; van der Pal HJ; Neggers SJ; van Grotel M; M van den Heuvel-Eibrink M
    Pediatr Hematol Oncol; 2017 Mar; 34(2):120-129. PubMed ID: 28590156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hearing Loss Risk in Pediatric Patients Treated with Cranial Irradiation and Cisplatin-Based Chemotherapy.
    Cohen-Cutler S; Wong K; Mena V; Sianto K; Wright MA; Olch A; Orgel E
    Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1488-1495. PubMed ID: 33677052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.